Literature DB >> 8414041

Anti-neutrophil cytoplasmic antibodies in vasculitis peripheral neuropathy.

C H Chalk1, H A Homburger, P J Dyck.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) have been reported to be specific serologic markers of systemic necrotizing vasculitis. We looked for ANCA in 166 consecutive patients referred for evaluation of peripheral neuropathy, wondering if ANCA might be helpful in diagnosing vasculitic neuropathy. ANCA were found in four of six patients with vasculitic neuropathy. However, false-positive results limited the diagnostic usefulness of ANCA in peripheral neuropathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414041     DOI: 10.1212/wnl.43.9.1826

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Acute fulminant neuropathy in a patient with Churg-Strauss syndrome.

Authors:  K K Ng; H M Yeung; K T Loo; H M Chan; C K Wong; P C Li
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

2.  Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis.

Authors:  Luigi Cattaneo; Elisabetta Chierici; Laura Pavone; Chiara Grasselli; Paolo Manganelli; Carlo Buzio; Giovanni Pavesi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-13       Impact factor: 10.154

3.  P-ANCA vasculitic neuropathy with 12-year latency between onset of neuropathy and systemic symptoms.

Authors:  Steven A Greenberg
Journal:  BMC Neurol       Date:  2002-10-31       Impact factor: 2.474

4.  High PR3-ANCA positivity in a patient with chronic inflammatory demyelinating polyneuropathy.

Authors:  Masanori Kurihara; Yu Kurata; Izumi Sugimoto; Yuki Hatanaka; Yasuhisa Sakurai
Journal:  eNeurologicalSci       Date:  2016-10-05

5.  Myelin- and microbe-specific antibodies in Guillain-Barré syndrome.

Authors:  J Terryberry; M Sutjita; Y Shoenfeld; B Gilburd; D Tanne; M Lorber; I Alosachie; N Barka; H C Lin; P Youinou
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.